Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers compared regimens prescribed to pregnant women in their second trimester.
Findings suggest exposure to antiretrovirals, including dolutegravir, during pregnancy does not raise the risk of neural tube defects.
Researchers at George Washington University take a look.
A major plus of the implant is that it can be easily removed if necessary.
However, an analysis of Swiss people with HIV found no significant change in the suicide rate in more recent years.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
Updating previous, similar findings, researchers have now reported on 96-week data from a pair of ongoing trials.
A late-stage trial randomized people taking a stable HIV regimen to switch to Dovato or stay on their current antiretrovirals.
However, Tivicay plus Descovy was associated with greater weight gain, especially among women.
Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.
The Food and Drug Administration has approved a new treatment for people living with HIV.
Changes include new information about risks associated with dolutegravir during pregnancy and removal of older drugs owing to toxicities.
Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.
Researchers examined outcomes among a group of people in middle- and low-income nations who switched to the integrase inhibitor.
This held true even among those with resistance to nucleoside/nucleotide reverse transcriptase inhibitors.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.